Natera (NTRA) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6323071042

Natera, Inc. is a global diagnostics company specializing in molecular testing services. The company offers a diverse range of products tailored for various medical needs.

One of Natera's flagship products is Panorama, a non-invasive prenatal test designed to screen for chromosomal abnormalities in fetuses, particularly in twin pregnancies. Horizon carrier screening is another key product that identifies genetic variations in individuals and couples that could lead to specific genetic conditions.

Vistara single-gene NIPT is a screening test focusing on 25 single-gene disorders responsible for severe skeletal, cardiac, and neurological conditions. Spectrum provides preimplantation genetic tests for couples undergoing IVF, while Anora aids in analyzing miscarriage tissue.

Empower is Natera's hereditary cancer screening test, and the company also offers a non-invasive prenatal paternity product for couples to establish paternity pre-birth.

Furthermore, Natera's innovative products include Signatera, a ctDNA blood test for disease monitoring in cancer patients, Altera comprehensive genomic profiling for tissue-based analysis, and Prospera for assessing rejection in kidney transplant patients.

The company's offerings extend to Renasight, a kidney gene panel test, and Constellation, a cloud-based software for laboratory customers to access advanced algorithms and bioinformatics.

Natera reaches its customers through a combination of direct sales and partnerships with laboratory and distribution channels. It collaborates with industry leaders like BGI Genomics Co., Ltd. and Foundation Medicine, Inc., to advance genetic testing technology and personalized monitoring solutions.

Founded in 2003, Natera is headquartered in Austin, Texas, and continues to innovate in the field of molecular diagnostics. For more information, visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Natera (NTRA) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Natera (NTRA) - Stock Price & Dividends

NTRA Stock Overview

Market Cap in USD 11,368m
Sector Healthcare
Industry Diagnostics & Research
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2015-07-02

NTRA Stock Ratings

Growth 5y 5.43
Fundamental -4.54
Dividend -
Rel. Performance vs Sector 4.67
Analysts 4.41/5
Fair Price Momentum 92.59 USD
Fair Price DCF -

NTRA Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

NTRA Growth Ratios

Growth 12m 77.29%
Growth Correlation 12m 51%
Growth Correlation 3m 82%
CAGR 5y 37.25%
Sharpe Ratio 12m 1.49
Alpha vs SP500 12m 46.01
Beta vs SP500 5y weekly 1.42
ValueRay RSI 38.67
Volatility GJR Garch 1y 45.04%
Price / SMA 50 7.54%
Price / SMA 200 49.65%
Current Volume 1182.1k
Average Volume 20d 1416.8k

External Links for NTRA Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of NTRA stocks?
As of April 16, 2024, the stock is trading at USD 90.42 with a total of 1,182,121 shares traded.
Over the past week, the price has changed by -5.25%, over one month by +1.01%, over three months by +43.73% and over the past year by +75.91%.
What is the forecast for NTRA stock price target?
According to ValueRays Forecast Model, NTRA Natera will be worth about 104.2 in April 2025. The stock is currently trading at 90.42. This means that the stock has a potential upside of +15.2%.
Issuer Forecast Upside
Wallstreet Target Price 95.3 5.43%
Analysts Target Price 71.2 -21.3%
ValueRay Target Price 104.2 15.2%